###### Key questions

What is already known about this subject?
=========================================

1.  Although CT angiography (CTA) reduces the rate of invasive coronary angiography (ICA) showing no obstructive coronary artery disease (CAD) compared with functional testing, the rate remains significant with this approach. The observational PLATFORM (Prospective Longitudinal Trial of FFR~CT~: Outcome and Resource Impacts) study showed that in patients with suspected CAD, substitution of an initial invasive strategy with CTA, in addition to CT-derived fractional flow reserve (FFR~CT~) if abnormal, was associated with a high rate of cancellation of ICA, thereby reducing the proportion of ICA showing no obstructive CAD, with no increase in adverse clinical outcomes.

What does this study add?
=========================

1.  This study showed that in the subgroup of patients enrolled in the PLATFORM study in Germany, where the rate of ICA is higher compared with other European countries or the USA, a greater proportion of patients in the CTA/FFR~CT~ group had their ICA cancelled, resulting in a lower proportion of ICA showing no obstructive CAD compared with the main study.

How might this impact on clinical practice?
===========================================

1.  This report suggests that in healthcare systems with higher rates of ICA, the absolute benefit of an initial CTA/FFR~CT~ strategy over an initial invasive strategy for investigation of suspected stable CAD may be more pronounced.

Introduction {#s1}
============

Stable chest pain is a common clinical presentation, often warranting further evaluation by non-invasive or invasive means.[@R1] A considerable proportion of patients require invasive coronary angiography (ICA) for definitive assessment, which has inherent risks and economic costs. Coronary CT angiography (CTA) may improve the efficiency of triage to ICA and potentially reduce radiation exposure.[@R2] However, this may come at a price of increased rates of coronary angiography and revascularisation compared with a strategy of non-invasive testing.[@R3]

CTA is limited by the provision of an exclusively anatomical assessment of the coronary vasculature. CT-derived fractional flow reserve (FFR~CT~) may address this shortcoming by providing functional information obtained by non-invasive means in addition to the anatomical information provided by coronary CTA.[@R4] Indeed, a number of trials have validated its use against invasive FFR.[@R5] The PLATFORM (Prospective Longitudinal Trial of FFR~CT~: Outcome and Resource Impacts) study, which enrolled patients at 11 centres across 6 European countries, showed that coronary CTA/FFR~CT~, when used as an alternative initial diagnostic strategy in patients planned for invasive catheterisation, was associated with a significantly lower rate of angiography showing no obstructive coronary artery disease (CAD) within 90 days,[@R2] with no difference in clinical outcomes or quality of life (QOL) at 1 year.[@R8] Furthermore, a resource use and cost analysis performed at 90 days and 1 year showed that an FFR~CT~ strategy was associated with reduced resource use and lower cost than an initial invasive strategy.[@R8]

In patients with suspected CAD, diagnostic evaluation practices may differ from country to country. Specifically, in the German healthcare system, a higher rate of coronary angiography is observed in comparison with other European countries or the USA.[@R10] Moreover, it has been suggested that the associated healthcare costs and reimbursement models may favour a more invasive approach to the evaluation of chest pain.[@R10] Against this background, the aim of this study is to compare an initial CTA/FFR~CT~ versus an ICA strategy in patients enrolled in the PLATFORM study at German sites, who were planned for ICA for investigation of chest pain, in terms of clinical efficacy and safety, resource use, cost and QOL.

Methods {#s2}
=======

Study population and study protocol {#s2a}
-----------------------------------

PLATFORM is an observational, prospective, consecutive cohort, comparative effectiveness study (ClinicalTrials.gov number NCT01943903). Full details of the study population, methods, endpoints and primary analysis have been previously reported.[@R2] In the main study, symptomatic outpatients ≥18 yearS of age without known CAD but with an intermediate likelihood of obstructive CAD, whose physician had planned either non-invasive tests or ICA to investigate suspected CAD were enrolled between September 2013 and November 2014. In this study, we report only the results in the group planned for ICA in the German subgroup (see online [supplementary figure 1](#SP1){ref-type="supplementary-material"}). Exclusion criteria included (1) acute coronary syndrome or clinical instability, (2) previously documented CAD, (3) contraindications for CTA or FFR~CT~, (4) need for urgent or emergent procedure or (5) ICA within 90 days before enrolment.
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###### Supplementary file

In patients with planned ICA, there were two prospective cohorts with consecutive enrolment, meaning that enrolment in the second cohort commenced only after completion of enrolment in the first. Patients in the first cohort received the usual invasive care testing already planned by the treating physician. In the second, patients received an initial CTA in lieu of the planned invasive testing, followed by FFR~CT~ analysis when requested by the treating site (advised if the CTA revealed ≥30% coronary stenosis). Non-invasive and invasive diagnostic testing (including CTA) was performed and interpreted on-site. All CTAs used a ≥64-slice multidetector, single-source or dual-source CT scanner and followed scanning protocols satisfying quality standards of the Society of Cardiac Computed Tomography.[@R13] Quantitative coronary angiography (QCA) and FFR~CT~ measurements were performed by independent core laboratories. QCA measurements were performed using QAngio software (Medis, The Netherlands) according to standard procedures.[@R14] FFR~CT~ analysis was performed centrally by HeartFlow (Redwood City, California, USA), as previously described.[@R5] In brief, three-dimensional blood flow simulations in the coronary arteries were performed using proprietary software with quantitative image quality analysis, image segmentation and physiological modelling using computational fluid dynamics. Coronary blood flow was simulated under conditions that modelled intravenous adenosine to mirror pressure and flow data and the FFR numeric values obtained during ICA.[@R2] The lowest FFR~CT~ numeric value in each coronary artery and colour-scale representations of the coronary vasculature showing FFR~CT~ values in vessels \>1.8 mm in diameter were provided to clinical sites. Local clinicians made all subsequent decisions regarding clinical management, following standard practice, including whether to alter management based on FFR~CT~ results. Optimal medical therapy was encouraged in both groups. This report includes rates of occurrence of the primary endpoint at 90 days, in addition to all final 1-year clinical, safety, QOL and economic results (using German cost weights) for the German subgroup. Ethical approval was obtained from local institutional review boards at each enrolling centre, and all patients provided written consent. The study was conducted in accordance with the Declaration of Helsinki.

Endpoints and definitions {#s2b}
-------------------------

The primary endpoint was the rate of ICA at ≤ 90days showing no obstructive CAD in patients with invasive testing planned before enrolment in the usual invasive care cohort versus the initial CTA/FFR~CT~ cohort. Obstructive CAD was defined as stenosis of ≥50% in any coronary artery in a vessel ≥2.0 mm in diameter by core laboratory QCA or invasive FFR \<0.80 in the absence of this degree of stenosis. Secondary endpoints included clinical, economic and QOL outcomes at 1 year. The clinical secondary endpoints included the following: (1) a composite of major cardiovascular events (MACE) at 1 year, including all-cause mortality, myocardial infarction (MI) and unplanned hospitalisation for chest pain leading to urgent revascularisation and (2) MACE plus vascular events within 14 days of procedures. MACE were adjudicated by an event adjudication committee blinded to the treatment groups based on standard, prospectively determined definitions.[@R17] Cumulative radiation exposure from all cardiovascular tests and procedures was determined over 1 year after enrolment, as previously described.[@R2]

The use of key medical resources, including non-invasive stress tests, CTA, invasive tests, coronary revascularisation procedures and clinical events, was demonstrated from study enrolment through 1 year. Cumulative medical costs (in euro) over 1 year were calculated on a per-patient basis by multiplying a standardised cost weight for each resource by the number of times that resource was used. Cost data were obtained using reimbursement rates for privately insured patients from the 2016 German doctor's fee schedule (GOÄ) for outpatient examinations and the 2016 German Diagnosis-Related Groups (G-DRG) system for inpatient investigations. The G-DRG system operates on a flat-fee principle based on the final documented diagnosis on discharge, taking into account factors such as comorbidities and length of stay. GOÄ reimbursement, on the other hand, operates on a fee-for-service basis for privately insured patients. When calculating the difference in subsequent costs between patients with the FFR~CT~ strategy versus the conventional strategy, the FFR~CT~ cost weight was set at zero, as there is no G-DRG or GOÄ cost weight at this time. QOL was assessed at baseline and one year using the Seattle Angina Questionnaire (SAQ), the EuroQOL scale (EQ-5D) and the EuroQOL visual analogue scale, and the magnitude of change was compared between patients in the usual invasive care cohort versus the initial CTA/FFR~CT~ cohort.

Follow-up and analysis {#s2c}
----------------------

Patients were followed up by clinic visit at 90 days, 6 months and 1 year from enrolment. Data were analysed at 90 days and 1 year. The country of enrolment was a prespecified subgroup in the PLATFORM study.

Statistical analysis {#s2d}
--------------------

Baseline characteristics were summarised and compared across usual care and CTA/FFR~CT~-guided care cohorts. Continuous data are presented as mean ± SD and were compared using Student's t-test or the Wilcoxon rank-sum test. Categorical variables are presented as counts (percentages) and were compared using the Pearson χ^2^ test or Fisher's exact test, where the expected cell value was \<5. The level of statistical significance was set to 0.0025 using the Bonferroni correction to adjust for multiple comparisons.

Endpoints were compared between the FFR~CT~-guided and usual care management strategies. All analyses were performed on an intention-to-treat basis. The risk difference and 95% CI were determined, and a one-sided Wald test (α error=0.025) for a risk difference \<0 evaluated whether CTA/FFR~CT~ was superior compared with usual testing. Analysis of the secondary endpoints at 1 year was determined in both cohorts. Cumulative radiation exposure was compared between groups using Student's t-test and the Wilcoxon rank-sum test and is presented as mean±SD and median (IQR). For economic analyses, unadjusted costs were compared between strategies using the non-parametric Wilcoxon rank-sum test on all patients and in the propensity-matched cohorts. A 95% CI for the difference in mean per-patient cost between usual care and FFR~CT~-guided care cohorts was determined using empirical bootstrap resampling with 100 000 replicates. The Wilcoxon signed-rank test was used to analyse changes in QOL scores from baseline to 1 year of follow-up for the entire cohort, and the Wilcoxon rank-sum test was used to compare QOL changes between groups. Changes in medication use from baseline to 1 year of follow-up were compared between groups using logistic regression fit using generalised estimating equations. There were no specific methods employed to account for missing data or loss to follow-up. All statistical assessments were performed by statisticians at HeartFlow, and analyses were performed using SAS version 9.3 (Cary, North Carolina, USA). A p value \<0.05 was considered statistically significant, unless otherwise specified.

Results {#s3}
=======

Patients {#s3a}
--------

Between September 2013 and November 2014, 116 patients who were planned for ICA were enroled at the three participating German sites ; 64 patients were allocated to usual care, and 52 patients were allocated to CTA/FFR~CT~. Pre-enrolment non-invasive testing had been done in 16 of the 52 patients in the CTA/FFR~CT~ and 41 of the 64 patients in the usual care group (p\<0.001). Complete follow-up data at 1 year was available for all but 5 patients in each group. A patient study flow chart is shown in online [supplementary figure 1](#SP1){ref-type="supplementary-material"}.

Baseline demographics and clinical characteristics are shown in [table 1](#T1){ref-type="table"}. Compared with the FFR~CT~ cohort, patients in the usual care cohort were older, had a higher incidence of diabetes and had a higher pretest probability of obstructive CAD than the CTA/FFR~CT~ cohort.

###### 

Baseline characteristics of study participants

  ------------------------------------------------------------------------------------------------
  **Variable**                                  **Planned invasive test**\               
                                                **(n=116)**                              
  --------------------------------------------- ---------------------------- ----------- ---------
  Demographics                                                                           

   Age, years                                   63.6±11.6                    55.3±10.2   \<0.001

   Female sex                                   25 (39.1)                    24 (46.2)   0.41

   Racial/ethnic minority (self-reported)       1 (1.6)                      1 (1.9)     

  Cardiac risk factors                                                                   

   Hypertension                                 45 (70.3)                    28 (53.8)   0.07

   Diabetes                                     12 (18.8)                    3 (5.8)     0.04

   Dyslipidaemia                                15 (23.4)                    10 (19.2)   0.58

   Current or past tobacco use                  33 (51.6)                    26 (50.0)   0.51

   Pretest probability of obstructive CAD^\*^   54.5±17.1                    44.6±16.1   0.002

  Anginal type                                                                           0.22

   Typical angina                               19 (29.7)                    17 (32.7)   

   Atypical angina                              42 (65.6)                    35 (67.3)   

   Non-cardiac chest pain                       3 (4.7)                      0 (0.0)     
  ------------------------------------------------------------------------------------------------

Data shown as mean±SD or number (percentage). \*Pretest probability of obstructive CAD±SD calculated by the updated Diamond and Forrester score.[@R18]

CAD, coronary artery disease; FFR~CT~, fractional flow reserve estimated using CT.

By study design, all patients in the CTA/FFR~CT~ group underwent CTA. FFR~CT~ analysis of CTA images was indicated in 30 cases (57.7%), 25 of which were suitable for same. ICA was performed in 100% of patients in the usual care cohort and in 12 patients (23.1%) in the CTA/FFR~CT~ cohort, with the remainder of invasive tests being cancelled by the treating physician based on the CTA/FFR~CT~ result (see online [supplementary figure 1](#SP1){ref-type="supplementary-material"}).

A 90-day coronary revascularisation was performed in 22 patients (19.0%) in total: 14 patients (21.9%) in the usual care cohort and 8 patients (15.4%) in the FFR~CT~ cohort. Between 90 days and 1 year, no patient in either cohort had a new unplanned revascularisation, while 1 patient (1.6%) in the usual care cohort had a repeat revascularisation procedure. Medications at 1 year of follow-up did not differ significantly between the CTA/FFR~CT~ and usual care groups: aspirin (25/47 (53%) vs 36/59 (61%), p=0.42), clopidogrel (7/47 (15%) vs 6/59 (10%), p=0.46) and any statin (21/47 (45%) vs 35/59 (59%), p=0.13).

Primary endpoint {#s3b}
----------------

The primary endpoint of ICA showing no obstructive CAD at 90 days occurred in 55 of the 64 (85.9%) patients in the usual care group compared with only 4 of the 52 (7.7%) patients in the CTA/FFR~CT~ group (risk difference 78.2%, 95% CI 67.1 to 89.4, p\<0.001, as shown in [figure 1](#F1){ref-type="fig"}).

![Rates of occurrence of the primary endpoint by evaluation strategy. The primary endpoint occurred in 85.9% and 7.7% of patients in the usual care and FFR~CT ~cohorts, respectively (risk difference 78.2%, 95% CI 67.1-89.4, p\<0.001). 76.9% of patients in the FFR~CT ~cohort had their ICA cancelled on the basis of their CTA/FFR~CT ~result. CAD=coronary artery disease; FFR~CT~=fractional flow reserve estimated using computed tomography; ICA=invasive coronary angiography; Obst CAD=obstructive coronary artery disease.](openhrt-2016-000526f01){#F1}

Clinical efficacy and safety outcomes at 1 year {#s3c}
-----------------------------------------------

There were no cases of MACE at 1 year in either group. No patients in the CTA/FFR~CT~ group versus two patients (3.1%) in the usual care group had vascular complications, both related to ICA (risk difference 3.1%, 95% CI −12.29 to 18.44).

There were no adverse clinical events at 1-year follow-up in any of the 40 patients who had their ICA cancelled on the basis of their CTA/FFR~CT~ result; 2 (5.0%) of these patients required an initial ICA during 1-year follow-up, both of which were performed because of a subsequent clinical presentation with chest pain and both showing no obstructive CAD.

Cumulative radiation exposure at 1 year was significantly lower in the FFR~CT~ cohort compared with the usual care cohort, with mean values of 7.28±9.33 versus 9.80±6.73 mSv and median values of 3.68 (IQR 1.69--8.73) versus 7.00 (IQR 7.00--7.00) mSv, respectively (p\<0.001). One-year clinical outcomes are shown in [table 2](#T2){ref-type="table"}.

###### 

One-year clinical outcomes according to study group

  ----------------------------------------------------------------------------------------------------------------------------------------
                                                                                  **Planned invasive test**\                     
                                                                                  **n= 116**                                     
  ------------------------------------------------------------------------------- ---------------------------- ----------------- ---------
  Invasive catheterisation without obstructive CAD by core lab QCA (at 90 days)                                                  

   Number of patients (%)                                                         55 (85.9)                    4 (7.7)           \<0.001

   Risk difference, % (CI)                                                        78.2 (67.1 to 89.4)                            

  MACE                                                                                                                           

   No of patients (%)                                                             0 (0)                        0 (0)             

  MACE or vascular complications                                                  2 (3.1)\                     0 (0)\            NS
                                                                                  CI 0.38 to 10.84             CI 0.00 to 6.85   

   Risk difference, % (CI)                                                        3.1 (--12.29 to 18.44)                         

  Cumulative radiation exposure                                                                                                  \<0.001

   Mean±SD, mSv                                                                   9.80 (6.73)                  7.28 (9.33)       

   Median (IQR), mSv                                                              7.00\                        3.68\             
                                                                                  (7.00, 7.00)                 (1.69, 8.73)      
  ----------------------------------------------------------------------------------------------------------------------------------------

CAD, coronary artery disease; FFR~C~**~T~**, fractional flow reserve estimated using CT; MACE, major adverse cardiovascular events; MI, myocardial infarction; NS, non-significant; QCA, quantitative coronary angiography.

Resource use and economic outcomes at 1 year {#s3d}
--------------------------------------------

Resource use over 1 year is shown in [table 3](#T3){ref-type="table"}, and cost weights are shown in online [supplementary table 1](#SP1){ref-type="supplementary-material"}. As there is currently no cost weight available for FFR~CT~, we set the cost weight at the cost of CTA plus zero for the initial estimate. The mean 1-year patient cost of cumulative medical care was significantly lower in the FFR~CT~ group, at €4217±€9740 compared with €6894±€7379 in the usual care group (p\<0.001). In addition, more patients in the FFR~CT~ group had low costs than in the usual care group, with median costs of €465 (IQR €2930) versus €5243 (IQR €4326), respectively (p\<0.001). Cumulative medical costs are shown in [figure 2](#F2){ref-type="fig"}. In a sensitivity analysis, we recalculated the 1-year costs using a series of cost weights that were multiples of the cost weight for CTA and compared these costs with the costs of a usual care strategy. A cost benefit for CTA/FFR~CT~ over usual care was maintained up to the value of 14 times the cost of CTA, at €6894 versus €6506, respectively, p=0.02.

###### 

Resource use over 12 months

  ------------------------------------------------------------------
                                  **Planned invasive test**\   
                                  **n=116**                    
  ------------------------------- ---------------------------- -----
  Non-invasive tests                                           

   Stress ECG                     6                            12

   Stress echo                    3                            2

   Stress nuclear                 1                            0

   MRI                            2                            0

   CTA                            1                            52

   FFR~CT~                        0                            25

  Invasive procedures                                          

   Diagnostic ICA                 61                           9

   ICA with PCI                   11                           10

   FFR~INV~                       2                            1

   Intravascular ultrasound       0                            0

   Optical coherence tomography   1                            0

  Coronary revascularisation                                   

   Percutaneous intervention      12                           10

   Stents per patient (mean)      2.1                          1.6

   Bypass surgery                 4                            1

  Hospital days                   122                          65

  Clinic visits                   20                           19
  ------------------------------------------------------------------

Data shown as number of times used.

CTA, CT angiography; FFR~CT~, fractional flow reserve estimated using CT; FFR~INV~, fractional flow reserve determined by ICA; ICA, invasive coronary angiography; PCI, percutaneous coronary intervention.

![One-year costs by evaluation strategy. Box plot showing median and interquartile range of cumulative 1-year medical costs calculated on a per patient basis according to treatment strategy when CTA/FFR~CT~ is given the same cost weight as CTA alone. The vertical axis indicates cumulative medical costs at one year. The top line of each box indicates the 75^th^ percentile, the dashed line within each box indicates the 50^th^ percentile (median) and the line at the bottom of each box represents the 25^th^ percentile. The triangles represent mean costs. Both median and mean costs were significantly lower in the CTA/FFR~CT ~cohort compared with the usual care cohort. CTA=computed tomography angiography; ICA=invasive coronary angiography; FFR~CT~=fractional flow reserve estimated using computed tomography.](openhrt-2016-000526f02){#F2}

QOL outcomes at 1 year {#s3e}
----------------------

Functional status and QOL scores improved from baseline to 1-year follow-up to a greater degree in the FFR~CT~ cohort compared with the usual care cohort, regardless of the score used. This difference was statistically significant when the EQ-5D score was used. Respective mean improvements using all three scores were as follows: +18.68 and +22.36 units on the SAQ (p=0.22); +0.03 versus +0.09 units on the EQ-5D (p=0.04) and -0.07 versus +5.09 units on the Visual Analogue Scale (p=0.51). Changes in QOL scores are demonstrated in [figure 3](#F3){ref-type="fig"}.

![Change in quality-of-life scores from baseline to 1 year by evaluation strategy. The vertical axes indicate changes in quality of life scores from baseline to 1 year, with a greater improvement seen in the FFR~CT ~cohort compared with the usual care cohort, regardless of the score used. This difference was statistically significant when the EQ-5D score was used. FFR~CT~=fractional flow reserve estimated using computed tomography, SAQ=Seattle Angina Questionnaire, EQ-5D=EuroQOL, VAS=visual analogue scale for health state.](openhrt-2016-000526f03){#F3}

Discussion {#s4}
==========

The main finding of our analysis was that in patients with a planned invasive strategy for investigation of suspected CAD enrolled in a consecutive cohort study at German sites, a CTA/FFR~CT~ strategy was associated with a significantly lower rate of ICA showing no obstructive CAD compared with those who received usual care. Moreover, an initial CTA±FFR~CT~ strategy was associated with a high rate of cancellation of ICA. Furthermore, CTA/FFR~CT~ was associated with significantly lower cumulative radiation exposure, significantly lower medical resource use and cost and greater improvement in QOL at 1-year follow-up.

One of the limitations of the use of CTA in routine practice is that it has low specificity for obstructive CAD and may increase the rate of referral for ICA. The PLATFORM study data suggest that by using CTA, with FFR~CT~ as required, due to the known higher specificity for obstructive CAD, this issue might be addressed in a clinically relevant way.[@R7]

It is well recognised that in patients presenting with chest pain with intermediate risk of obstructive CAD, considerable variation exists in relation to diagnostic practices. In particular, in Germany, the rate of ICA is higher than in other European countries or in the USA.[@R10] However, the ratio of revascularisation (both percutaneous and surgical) to ICA is lower in Germany,[@R10] which would imply that a higher proportion of ICA performed shows no obstructive CAD. Against this background, the analysis of outcomes of patients enroled in the PLATFORM study at German sites might be expected to be of particular interest.

In terms of the primary endpoint, the findings of this report are generally consistent with those of the main PLATFORM study, although the benefits of an initial CTA/FFR~CT~ strategy in patients planned for ICA may be even more pronounced in the setting of the German healthcare system. In this respect, the risk difference in the occurrence of the primary endpoint between the CTA/FFR~CT~ group and the usual care group was greater than in the main PLATFORM study (78.2% vs 61.0%, respectively). This is a result of both a higher rate of occurrence of the primary endpoint in the usual care cohort in the German subgroup compared with the main study (86% vs 73%, respectively), which is to be expected given the higher rate of ICA in Germany, and a lower rate of occurrence of the primary endpoint in the FFR~CT~ cohort in the German subgroup compared with the main study (8% vs 12%, respectively), which can be partly explained by a higher rate of cancellation of ICA based on the CTA/FFR~CT~ result in this cohort in the German subgroup (77%) compared with the main study (61%). The rate of the primary endpoint in the usual care group as determined by core laboratory QCA was higher than the site-reported rate (86% vs 69%, respectively). However, this did not change the overall results and is consistent with known differences between the two assessment techniques.

It is also noteworthy that a lower proportion of patients who underwent CTA were referred for FFR~CT~ analysis in the German subgroup than in the main study (57.7% vs 69.4%, respectively). This is likely because more patients with normal coronary arteries were filtered out by CTA alone, without the need for FFR~CT~ analysis. This is supported by the fact that a higher proportion of ICA was cancelled in patients in the CTA cohort in the German subgroup compared with the main study, despite the lower rate of FFR~CT~ analysis. In addition, there was no significant difference in rates of measurable CTA in those referred for FFR~CT~ analysis between the German subgroup and the main study (83.3% vs 87.3%, respectively). Despite the use of a dedicated evaluation protocol, it is possible that a proportion of patients with obstructive CAD remain undetected. In this respect, in the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps), the addition of FFR~CT~ to CTA alone, increased the specificity from 34% to 79% (compared with 83% with ICA). In addition, the sensitivity of this approach was 86% (compared with 64% for ICA).[@R7]

In terms of secondary endpoints, the absence of MACE among patients in the CTA/FFR~CT~ group who had their ICA cancelled is important (and consistent with findings in the overall PLATFORM population), with only two of these patients undergoing ICA during 1-year follow-up, both showing no obstructive CAD. The finding of lower cumulative medical costs over 1 year in the CTA/FFR~CT~ cohort compared with the usual care cohort is also consistent with findings from the main PLATFORM study. Furthermore, when German cost weights were used to calculate cumulative medical costs at 1 year for all patients enrolled in the main PLATFORM study, this effect persisted (mean costs of €5961 vs €8865 and median costs of €5271 vs €556, respectively, p\<0.001).

In some respects, our findings are consistent with those from the randomised CONSERVE (Coronary computed tomographic angiography for selective cardiac catheterization: relation to cardiovascular outcomes, cost effectiveness and quality of life) trial, which also studied patients with an intermediate pretest probability of obstructive CAD, planned for ICA and compared outcomes between those who proceeded to ICA as planned (direct ICA) versus those who underwent initial CTA (without FFR~CT~) with ICA, if necessary (selective ICA). In that study, selective ICA did reduce the rate of ICA and revascularisation, as well as overall cost, although there was no difference in clinical adverse outcomes at 1 year. However, in contrast to PLATFORM, the investigational approach did not reduce the rate of ICA showing no obstructive CAD compared with direct ICA.[@R20]

Interestingly, cumulative radiation exposure at 1 year was significantly lower in the FFR~CT~ cohort in the German subgroup, an effect not observed in the main PLATFORM study. While cumulative radiation dose in the usual care cohort was similar in the German substudy and the main study, it was much lower in the FFR~CT~ cohort (mean radiation dose 7.28 vs 10.72 mSv and median 3.68 vs 7.94 mSv, respectively). Finally, the greater improvement in QOL in the FFR~CT~ cohort in the German subgroup is consistent with the main study, although this was only statistically significant for the German subgroup. The reason for this greater degree of improvement in the FFR~CT~ group is unclear and must be interpreted with caution due to the non-randomised, unblinded nature of the study and the risk of a type I error. However, it is possible that the avoidance of an invasive procedure, even if no further intervention was required, and the overall lower number of hospital days may have contributed to the observed differences.

Although there are randomised clinical trial data to support the role of CTA in the investigation of stable chest pain, some clinical trials have shown that CTA alone for the investigation of stable chest pain is associated with a higher rate of ICA showing no obstructive CAD and, potentially a higher rate of revascularisation in the absence of knowledge of lesion functional severity.[@R19] While our study suggests some benefit from a CTA/FFR~CT~ strategy in reducing rates of ICA showing no obstructive disease compared with routine CTA, it should be acknowledged that the design of this study does not permit direct assessment of the incremental benefit of CTA/FFR~CT~ over CTA alone. Randomised data are needed to clarify this issue.

Limitations {#s4a}
-----------

This study has a number of important limitations that must be taken into account. First, group allocation was not randomised: patients in the FFR~CT~ arm were significantly younger than those in the usual care arm, with a lower incidence of diabetes and lower pretest probability of obstructive CAD. This may have led to increased rates of cancellation of ICA and lower rates of FFR~CT~ utilisation in the CTA/FFR~CT~ group. Although this likely increased the difference in occurrence of the primary endpoint between treatment groups, it is unlikely to have changed the overall result. Second, the sample size was relatively small, and the study was not equipped to show a difference in clinical events, such as MACE. In addition, the number of clinical events occurring during follow-up was relatively low. Therefore, failure to detect a difference between groups does not reliably rule out a difference. Third, patients at intermediate risk of obstructive CAD were referred for ICA based on the judgement of the referring physician, as ICA was deemed to be appropriate, even though non-invasive testing was not performed in all patients. Although this approach may be considered according to current guidelines,[@R1] the specific reasons as to why non-invasive testing was not undertaken were not analysed as part of the study protocol, and this limits the external validity of the findings. Finally, the cost weights used for outpatient tests in this study apply to reimbursement for investigations and procedures performed in privately insured patients. Therefore, the cost analysis is not generalisable to all patients within the German healthcare system.

Conclusion {#s4b}
----------

In patients with stable chest pain planned for invasive coronary angiography at German sites, an initial CTA/FFR^CT^ strategy compared with usual care was associated with a significantly lower rate of ICA showing no obstructive CAD. This strategy was also associated with lower cumulative radiation exposure, lower cost and improved quality of life, with no increase in adverse clinical events at 1-year follow-up.
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